Statin use poses low risk of hepatic injury in liver disease

Statin use poses low risk of hepatic injury in liver disease
Statin use poses low risk of hepatic injury in liver disease

HealthDay News -- Statin initiation is associated with lower overall incidence of hospitalization due to severe hepatic injury in patients with chronic liver disease, results of a study published in the Journal of Gastroenterology and Hepatology suggest.

To estimate the risk of severe hepatic injury associated with different statins in patients with chronic liver disease, Chia-Hsuin Chang, MD, PhD, of the National Taiwan University in Dou-Liou City, and colleagues conducted a nationwide population-based cohort study involving 37,929 subjects with chronic liver disease who started statin therapy.

Of the patients, 912 incident cases of hospitalization due to hepatic injury were identified during a total of 118,772 person-years of follow-up. For atorvastatin, lovastatin, fluvastatin, pravastatin, simvastatin, and rosuvastatin initiators, the incidence rates were 2.95, 2.49, 2.92, 1.94, 2.65, and 2.52 per 100,000 person-days, respectively.

There was no difference overall in the incidence with different statins. On further categorization of high- and low-dose statins, high-dose, but not low-dose, atorvastatin was significantly associated with increased risk of hospitalization due to hepatic injury (hazard ratio, 1.62; 95% CI: 1.29, 2.03).

"The overall incidence of hospitalization due to severe hepatic injury was low among statin initiators with chronic liver disease," concluded the study authors.

References

  1. Chang CH et al. Journal of Gastroenterology and Hepatology. 2014; doi: 10.1111/jgh.12657
Loading links....
You must be a registered member of Clinical Advisor to post a comment.
close

Next Article in Hepatology Information Center

Sign Up for Free e-newsletters